Finally, to evaluate the prognostic and clinicopathological significance of survivin as a potential biomarker in CRC we enrolled 15 eligible studies into our meta-analysis that were published between 1998 and 2012 [14], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34]. Here, BIRC5 is linked to colorectal carcinoma.